Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCWP-D017
- Development stage
- Preclinical
- Lead developer
- BC World Pharm
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
BCWP-D017 is a long-acting injectable (LAI) small molecule antipsychotic formulation under development by BC World Pharm. Designed to provide a sustained therapeutic effect over a two-month duration, BCWP-D017 utilizes the company's proprietary drug delivery system (DDS) technology to enable controlled release of the active antipsychotic agent. The formulation is intended for the treatment of schizophrenia and other psychotic disorders, aiming to improve patient compliance, maintain stable plasma drug concentrations, and reduce the risk of relapse compared to daily oral therapies.
- Other names
- BCWP D017BCWPD017BCWPD-017BCWPD 017
Beyond the preview
Go deeper on BCWP-D017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCWP-D017.